Research Article
No access
Published Online: 26 September 2014

Transcription-Mediated Chimeric RNAs in Prostate Cancer: Time to Revisit Old Hypothesis?

Publication: OMICS: A Journal of Integrative Biology
Volume 18, Issue Number 10

Abstract

Chromosomal rearrangements and fusion genes play important roles in tumor development and progression. Four high-frequency prostate cancer-specific fusion genes were recently reported in Chinese cases. We attempted to confirm one of the fusion genes, USP9Y-TTTY15, by reverse transcription PCR, but detected the presence of the USP9Y-TTTY15 fusion transcript in cancer samples, nonmalignant prostate tissues, and normal tissues from other organs, demonstrating that it is a transcription-induced chimeric RNA, which is commonly produced in normal tissues. In 105 prostate cancer samples and case-matched adjacent nonmalignant tissues, we determined the expression level of USP9Y-TTTY15 and a previously reported transcription-induced chimeric RNA, SLC45A3-ELK4. The expression levels of both chimeric RNAs vary greatly in cancer and normal cells. USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer. Although the expression level of SLC45A3-ELK4 is higher in cancer than normal cells, and a dramatic increase in its expression from normal to cancer cells is correlated with advanced disease, its expression level in cancer samples alone is not correlated with any clinical parameters. These data show that both chimeric RNAs contribute less to prostate carcinogenesis than previously reported.

Get full access to this article

View all available purchase options and get full access to this article.

References

Akiva P. (2005). Transcription-mediated gene fusion in the human genome. Genome Res 16, 30–36.
Boyd LK, Mao X, and Lu YJ. (2012). The complexity of prostate cancer: Genomic alterations and heterogeneity. Nat Rev Urol 9, 652–664.
Cocquet J, Chong A, Zhang G, and Veitia RA. (2006). Reverse transcriptase template switching and false alternative transcripts. Genomics 88, 127–131.
Edwards PA. (2010). Fusion genes and chromosome translocations in the common epithelial cancers. J Pathol 220, 244–254.
Fang W, Wei Y, Kang Y, and Landweber LF. (2012). Detection of a common chimeric transcript between human chromosomes 7 and 16. Biol Direct 7, 49.
Gingeras TR. (2009). Implications of chimaeric non-co-linear transcripts. Nature 461, 206–211.
Gronberg H. (2003). Prostate cancer epidemiology. Lancet 361, 859–864.
Guerra E, Trerotola M, Dell' Arciprete R, et al. (2008). A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 68, 8113–8121.
Iyer MK, Chinnaiyan AM, and Maher CA. (2011). ChimeraScan: A tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903–2904.
Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians 61, 69–90.
Kannan K, Wang L, Wang J, et al. (2011). Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 108, 9172–9177.
Kim DS, Huh JW, and Kim HS. (2007). HYBRIDdb: A database of hybrid genes in the human genome. BMC Genomics 8, 128.
Kim DS, Kim DW, Kim MY, et al. (2012). CACG: A database for comparative analysis of conjoined genes. Genomics 100, 14–17.
Kim P, Yoon S, Kim N, et al. (2010). ChimerDB 2.0—A knowledge base for fusion genes updated. Nucleic Acids Res 38, D81–85.
Kim RN, Kim A, Choi SH, et al. (2012). Novel mechanism of conjoined gene formation in the human genome. Funct Integr Genomics 12, 45–61.
Kohno T, Ichikawa H, Totoki Y, et al. (2012). KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18, 375–377.
Langmead B. (2010). Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics Chapter 11, Unit 11 17.
Lee K, Chae JY, Kwak C, Ku JH, and Moon KC. (2010). TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology 76, 1268e1267–1213.
Li H, Wang J, Mor G, and Sklar J. (2008). A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321, 1357–1361.
Magi-Galluzzi C, Tsusuki T, Elson P, et al. (2011). TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489–497.
Maher CA, Kumar-Sinha C, Cao X, et al. (2009). Transcriptome sequencing to detect gene fusions in cancer. Nature 458, 97–101.
Mao X, Yu Y, Boyd LK, et al. (2010). Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 70, 5207–5212.
McCracken M, Olsen M, Chen MS Jr., et al. (2007). Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57, 190–205.
Mitelman F, Johansson B, and Mertens F. (2007). The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7, 233–245.
Miyagi Y, Sasaki T, Fujinami K, et al. (2010). ETS family-associated gene fusions in Japanese prostate cancer: Analysis of 194 radical prostatectomy samples. Modern Pathol 23, 1492–1498.
Noel EE, Yeste-Velasco M, Mao X, et al. (2010). The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 176, 2607–2615.
Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16, 793–798.
Parra G. (2005). Tandem chimerism as a means to increase protein complexity in the human genome. Genome Res 16, 37–44.
Pikor LA, Ramnarine VR, Lam S, and Lam WL. (2013). Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 82, 179–189.
Prakash T, Sharma VK, Adati N, et al. (2010). Expression of conjoined genes: Another mechanism for gene regulation in eukaryotes. PLoS One 5, e13284.
Ren G, Liu X, Mao X, et al. (2012). Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer. Genes Chromosomes Cancer 51, 1014–1023.
Ren S, Peng Z, Mao J-H, et al. (2012). RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 22, 806–821.
Rickman DS, Pflueger D, Moss B, et al. (2009). SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69, 2734–2738.
Seshagiri S, Stawiski EW, Durinck S, et al. (2012). Recurrent R-spondin fusions in colon cancer. Nature 488, 660–664.
Shook SJ, Beuten J, Torkko KC, et al. (2007). Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 13, 5959–5964.
Soda M, Choi YL, Enomoto M, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566.
Thomson TM, Lozano JJ, Loukili N, et al. (2000). Fusion of the human gene for the polyubiquitination coeffector UEV1 with Kua, a newly identified gene. Genome Res 10, 1743–1756.
Tomlins SA, Laxman B, Dhanasekaran SM, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599.
Tomlins SA, Rhodes DR, Perner S, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648.
Zhang Y, Gong M, Yuan H, et al. (2012). Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Disc 2, 598–607.

Information & Authors

Information

Published In

cover image OMICS: A Journal of Integrative Biology
OMICS: A Journal of Integrative Biology
Volume 18Issue Number 10October 2014
Pages: 615 - 624
PubMed: 25188740

History

Published in print: October 2014
Published online: 26 September 2014
Published ahead of print: 4 September 2014

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Guoping Ren
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Yanling Zhang
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Xueying Mao
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Xiaoyan Liu
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Emma Mercer
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Jacek Marzec
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Dong Ding
Systems Biology Division and Propriumbio Research Center, Zhejiang-California International Nanosystems Institute (ZCNI), Zhejiang University, Hangzhou, Zhejiang Province, China.
Yurong Jiao
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Department of Pathology, The Yiwu Affiliated Hospital of Zhejiang University Medical College, Yiwu, China.
Qingchong Qiu
Systems Biology Division and Propriumbio Research Center, Zhejiang-California International Nanosystems Institute (ZCNI), Zhejiang University, Hangzhou, Zhejiang Province, China.
Yue Sun
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Biao Zhang
Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, China.
Department of Pathology, Haiyan People's Hospital, Jiaxing, China.
Marc Yeste-Velasco
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Claude Chelala
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Daniel Berney
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Yong-Jie Lu
*
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.

Notes

Address correspondence to:Yong-Jie LuCentre for Molecular OncologyBarts Cancer InstituteQueen Mary University of LondonCharterhouse SquareLondon EC1M 6BQUnited Kingdom
E-mail: [email protected]
orGuoping RenDepartment of PathologyThe First Affiliated HospitalZhejiang University Medical CollegeHangzhou 310029China
E-mail: [email protected]

Author Disclosure Statement

The authors declare that no competing financial interests exist.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top